Dabrafenib and/or Trametinib Rollover Study

NCT03340506 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Non Small Cell Lung Cancer
Solid Tumor
Rare Cancers
High Grade Glioma

Interventions

DRUG: dabrafenib
DRUG: trametinib

Sponsor

Novartis Pharmaceuticals